In patients with hormone receptor-positive and HER2-negative advanced breast cancer, these medications have shown to have a considerable therapeutic effect, including enhanced overall survival and progression-free survival (Sledge et al., 2020). The gene discussed is ERBB2; the disease is breast carcinoma.